Scholarlink

<p>This meta-analysis was conducted to assess the association between statin exposure and the incidence of adverse events (cirrhosis, cirrhosis decompensation, hepatocellular carcinoma (HCC), and all-cause mortality) in individuals with chronic viral hepatitis. Seventeen cohort studies were included in this analysis. The findings indicate that statin exposure in patients is associated with a significantly reduced incidence of HCC (HR = 0.56; <i>p</i> &lt; 0.001), all-cause mortality (HR = 0.63; <i>p</i> &lt; 0.001), cirrhosis (HR = 0.54; <i>p</i> &lt; 0.001), and cirrhosis decompensation rates (HR = 0.54; <i>p</i> &lt; 0.001). The lipophilic statins were particularly effective in reducing the incidence of HCC compared to controls (HR = 0.56; 95% CI 0.40–0.80), whereas hydrophilic statins did not exhibit significant benefits (HR = 0.83; 95% CI 0.63–1.10). Exposure to statins, particularly lipophilic statins, may be effective to reduce the incidence of adverse events in individuals with chronic viral hepatitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Statins exposure and adverse events in participants with chronic viral hepatitis: a meta-analysis based on cohort studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月25日

查看全文
  • Jiale Ruan,
  • Yingying Fang,
  • Xingfen Zhang,
  • Qiufeng Zhang,
  • Jian Song

摘要

This meta-analysis was conducted to assess the association between statin exposure and the incidence of adverse events (cirrhosis, cirrhosis decompensation, hepatocellular carcinoma (HCC), and all-cause mortality) in individuals with chronic viral hepatitis. Seventeen cohort studies were included in this analysis. The findings indicate that statin exposure in patients is associated with a significantly reduced incidence of HCC (HR = 0.56; p < 0.001), all-cause mortality (HR = 0.63; p < 0.001), cirrhosis (HR = 0.54; p < 0.001), and cirrhosis decompensation rates (HR = 0.54; p < 0.001). The lipophilic statins were particularly effective in reducing the incidence of HCC compared to controls (HR = 0.56; 95% CI 0.40–0.80), whereas hydrophilic statins did not exhibit significant benefits (HR = 0.83; 95% CI 0.63–1.10). Exposure to statins, particularly lipophilic statins, may be effective to reduce the incidence of adverse events in individuals with chronic viral hepatitis.